Inhibitory effects of a black cohosh (Cimicifuga racemosa) extract on prostate cancer

Planta Medica

Volumn 72, Issue 6, 2006, Pages 521-526

  Seidlová Wuttke, Dana ^a   Thelen, Paul ^a   Wuttke, Wolfgang ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Black cohosh; LNCaP cells; nu nu mice; Prostate cancer

Indexed keywords

CIMICIFUGA RACEMOSA EXTRACT;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CELL PROLIFERATION; CIMICIFUGA RACEMOSA; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

ANIMALIA; CIMICIFUGA DAHURICA; CIMICIFUGA RACEMOSA;

EID: 33744902381     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-931538     Document Type: Article

References (26)

1. Ryan CJ, Small EJ. Progress in detection and treatment of prostate cancer. Curr Opin Oncol 2005; 17: 257-60
2. Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 2000; 18: 52-74
3. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308
4. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002; 52: 213-35
5. Borst SE, Lee JH, Conover CF. Inhibition of 5{alpha}-reductase blocks prostate effects of testosterone without blocking anabolic effects. Am J Physiol Endocrinol Metab 2005; 288: E222-7
6. Chen W, Zouboulis CC, Orfanos CE. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996; 193: 177-84
7. Smith CM, Ballard SA, Worman N, Buettner R, Masters JR. 5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J Clin Endocrinol Metab 1996; 81: 1361-6
8. Negri-Cesi P, Poletti A, Colciago A, Magni P, Martini P, Motta M. Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate 1998; 34: 283-91
9. Jarry H, Thelen P, Christoffel V, Spengler B, Wuttke W. Cimicifuga racemosa extract BNO 1055 inhibits proliferation of the human prostate cancer cell line LNCaP. Phytomedicine 2005; 12: 178-82
10. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P. Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog Growth Factor Res 1995; 6: 273-84
11. Zhau HE, Li CL, Chung LW. Establishment of human prostate carcinoma skeletal metastasis models. Cancer 2000; 88: 2995-3001
12. Peehl DM, Cohen P, Rosenfeld RG. The insulin-like growth factor system in the prostate. World J Urol 1995; 13: 306-11
13. Culig Z, Hobisch A, Cronauer MV, Hittmair A, Radmayr C, Bartsch G et al. Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J Urol 1995; 13: 285-9
14. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004; 58: 130-44
15. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24
16. Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003; 44: 650-5
17. van Weerden WM, Romijn JC. Use of nude mouse xenograft models in prostate cancer research. Prostate 2000; 43: 263-71
18. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res 2005; 15: 57-62
19. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5: 21-8
20. Helterbrand JD, Higgs RE Jr, Iversen PW, Tysarczyk-Niemeyer G, Sato M. Application of automatic image segmentation to tibiae and vertebrae from ovariectomized rats. Bone 1997; 21: 401-9
21. Seidlova-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol 2003; 149: 351-62
22. Hostanska K, Nisslein T, Freudenstein J, Reichling J, Sailer R. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. Breast Cancer Res Treat 2004; 84: 151-60
23. Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Evaluation of cell death caused by triterpene glycosides and phenolic substances from Cimicifuga racemosa extract in human MCF-7 breast cancer cells. Biol Pharm Bull 2004; 27: 1970-5
24. Chen Y, Yu DC, Charlton D, Henderson DR. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000; 11: 1553-67
25. Rosen CJ. Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studies. Best Pract Res Clin Endocrinol Metab 2004; 18: 423-35
26. Spelsberg TC, Subramaniam M, Riggs BL, Khosla S. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol 1999; 13: 819-28